Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years

Published:2022 Issue:4 Volume:36 Page:1881-1886
ISSN:0258-851X
Container-title:In Vivo
language:en
Short-container-title:In Vivo

Author:

MATSUO MIOKO,YASUMATSU RYUJI,MASUDA MUNEYUKI,YAMAUCHI MORIYASU,WAKASAKI TAKAHIRO,HASHIMOTO KAZUKI,JIROMARU RINA,MANAKO TOMOMI,NAKAGAWA TAKASHI

Publisher

Anticancer Research USA Inc.

Subject

Pharmacology,General Biochemistry, Genetics and Molecular Biology,Cancer Research

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling;PharmacoEconomics;2024-08-23

2. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation;Cancers;2024-07-12

3. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab;Journal of Clinical Medicine;2024-04-23

4. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma;Oral Oncology;2024-02

5. Clinical analysis of pembrolizumab therapy for recurrent or metastatic head and neck cancer: A single center retrospective study;Toukeibu Gan;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP